Top tech and startup stories to start your day with
Theranautilus, a Bengaluru-based deeptech startup, will commence human trials of its nanorobot-based dental technology in November-December. The trials will initially involve around 30 patients, followed by a 300-patient multicentric trial to facilitate commercialization. Theranautilus plans to seek permission from the Central Drugs Standard Control Organisation (CDSCO) before commencing the trials.
The company's CEO, Peddi Shanmukh Srinivas, anticipates commercialization within two years for oral health applications and up to four to five years for oncology applications. Theranautilus is developing magnetically controlled nanorobots capable of targeted drug delivery, diagnostics, and treatment within the body, with its first commercial application focusing on dental care, specifically treating tooth sensitivity caused by enamel loss and gum recession.
Written by urgent.news from The Economic Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
